文献速递骨软组织肉瘤与黑色素瘤

药物组合临床前评估揭示Bcl-2/XL/W与MDM2共抑制为葡萄膜黑色素瘤潜在疗法

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
PubMed 文献 · Eur J Cancer · 2020-01-09

该研究通过对8株葡萄膜黑色素瘤(UM)细胞系进行30种通路抑制剂组合的体外筛选,发现Bcl-2/XL/W抑制剂ABT263使UM细胞对mTOR、MEK和MDM2抑制剂敏感。在6例UM患者来源异种移植(PDX)模型中,ABT263联合MDM2抑制剂HDM201显示协同效应趋势,而联合mTOR或MEK抑制剂未见协同。结果表明Bcl-2/XL/W与MDM2共抑制是UM有前景的治疗策略。

要点

  • Bcl-2/XL/W抑制剂ABT263可增敏UM细胞对mTOR、MEK和MDM2抑制剂的反应。
  • 在UM PDX模型中,ABT263联合MDM2抑制剂HDM201显示协同效应趋势。
  • ABT263联合mTOR或MEK抑制剂在UM PDX中未见协同作用。

核心结论

  • 抑制Bcl-2/XL/W可使UM细胞系对其他治疗增敏,Bcl-2/XL/W与MDM2共抑制是UM有前景的策略。

研究设计与样本

  • 体外筛选30种通路抑制剂组合,在8株UM细胞系中评估活力、细胞周期和凋亡;最佳协同组合进一步在6例UM PDX中评估。

主要发现

  • Bcl-2/XL/W抑制剂ABT263使UM细胞系对mTOR、MEK和MDM2抑制剂敏感。
  • mTOR抑制剂RAD001和MEK1/2抑制剂trametinib单药有效,但与ABT263联合在UM PDX中无协同。
  • ABT263与MDM2抑制剂HDM201联合在UM PDX中显示协同效应趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Uveal melanoma (UM) is a rare and malignant intraocular tumour with a dismal prognosis. Despite a good control of the primary tumour by radiation or surgery, up to 50% of patients subsequently develop metastasis for which no efficient treatment is yet available. METHODOLOGY: To identify therapeutic opportunities, we performed an in vitro screen of 30 combinations of different inhibitors of pathways that are dysregulated in UM. Effects of drug combinations on viability, cell cycle and apoptosis were assessed in eight UM cell lines. The best synergistic combinations were further evaluated in six UM patient-derived xenografts (PDXs). RESULTS: We demonstrated that the Bcl-2/XL/W inhibitor (ABT263) sensitised the UM cell lines to other inhibitors, mainly to mammalian target of rapamycin (mTOR), mitogen-activated protein kinase kinase (MEK) and murine double minute 2 (MDM2) inhibitors. mTOR (RAD001) and MEK1/2 (trametinib) inhibitors were efficient as single agents, but their combinations with ABT263 displayed no synergism in UM PDXs. In contrast, the combination of ABT263 with MDM2 inhibitor (HDM201) showed a trend for a synergistic effect. CONCLUSION: We showed that inhibition of Bcl-2/XL/W sensitised the UM cell lines to other treatments encouraging investigation of the underlying mechanisms. Furthermore, our findings highlighted Bcl-2/XL/W and MDM2 co-inhibition as a promising strategy in UM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Decaudin D, Frisch Dit Leitz E, Nemati F, et al. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. Eur J Cancer. 2020. PMID: 31927215. doi:10.1016/j.ejca.2019.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。